felt Thanks
We are excited to share an update about Lexeo’s HEROIC PKP2 clinical trial. Results to date highlights of this trial include the following: Completed enrollment of cohort 1 (low dose cohort) in the LX2020 HEROIC-PKP2 Phase 1/2 trial, with three people treated Early data, including safety and PKP2 protein expression, is expected in H1 2025.
Read More… from Update Regarding Lexeo’s HEROIC PKP2 Clinical Trial
Clinical Trial Now Enrolling for Patients with Dilated Cardiomyopathy (DCM) due to Genetic Mutations or Unknown Causes Bristol Myers Squibb is conducting a clinical trial in patients with DCM due to genetic mutations or unknown causes. Details of the study and eligibility requirements are listed below and participating in such research can help advance therapies
Please click on this link or the image above to view a recording of this webinar and learn about: Myths and Truths About Clinical Trials Industry experts discuss the Myths and Truths of Clinical Trials on a panel discussion Learn about the phases and average timeline for clinical trials Hear about the measures taken to ensure
Dilated cardiomyopathy, DCM, has many causes and can be acquired or genetic. Genetic means a disease-causing change, or “mutation”, has occurred in a relevant gene. That mutation may have occurred in prior generations or may be new as just having happened in a patient 1,2. This type of DCM is called genetic DCM. Research
Read More… from Clinical Trial Now Enrolling for Patients with Genetic DCM (MYH7)
